Literature DB >> 23163774

Adaptation and clonal selection models of castration-resistant prostate cancer: current perspective.

Muhammed Ahmed1, Long-Cheng Li.   

Abstract

Prostate cancer is a leading cause of cancer deaths in men worldwide. Management of the disease has remained a great challenge and even more so is the aggressive advanced stage with castration-resistant behavior. The mechanisms and timing of development of castration-resistant prostate cancer are unclear and remain debatable. Progression to castration-resistant prostate cancer is undoubtedly multifactorial, with a number of molecular-genetic aberrations implicated. However, a key question that remains unanswered is: when in the evolution of prostate cancer do the changes that confer castration resistance occur? Earlier attempts to address this question led to two proposed models: the "adaptation" and the "clonal selection" models. Although the prevailing hypothesis is the adaptation model, there is recent evidence in favor of the clonal selection model. Clarification of the model development of castration-resistant prostate cancer might significantly alter our diagnostic and therapeutic strategies, and potentially lead to improved outcome of management of this daunting condition. Here we review existing knowledge and current research findings addressing the timing of events in the course of prostate cancer progression to castration-resistant prostate cancer.
© 2012 The Japanese Urological Association.

Entities:  

Mesh:

Year:  2012        PMID: 23163774     DOI: 10.1111/iju.12005

Source DB:  PubMed          Journal:  Int J Urol        ISSN: 0919-8172            Impact factor:   3.369


  13 in total

Review 1.  Should docetaxel be standard of care for patients with metastatic hormone-sensitive prostate cancer? Pro and contra.

Authors:  K Fizazi; C Jenkins; I F Tannock
Journal:  Ann Oncol       Date:  2015-05-22       Impact factor: 32.976

2.  Stereotactic body radiation therapy (SBRT) delays the emergence of castration resistance in patients with oligometastatic prostate cancer.

Authors:  M I Martínez-Fernández; J L Pérez Gracia; I Gil-Bazo; R Martínez-Monge
Journal:  Clin Transl Oncol       Date:  2015-10-19       Impact factor: 3.405

3.  Long-Term Control of Oligometastatic Prostate Cancer After Stereotactic Body Radiotherapy in the Absence of Androgen Deprivation Therapy: A Case Report.

Authors:  Mark C Markowski; Philip Imus; Jean L Wright; Douglas Schottenstein; Channing J Paller
Journal:  Clin Genitourin Cancer       Date:  2017-02-27       Impact factor: 2.872

Review 4.  Cytoreductive radical prostatectomy in metastatic prostate cancer: Does it really make sense?

Authors:  Romain Mathieu; Stephan M Korn; Karim Bensalah; Gero Kramer; Shahrokh F Shariat
Journal:  World J Urol       Date:  2016-08-08       Impact factor: 4.226

5.  Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.

Authors:  Edoardo Francini; Steven Yip; Shubidito Ahmed; Haocheng Li; Luke Ardolino; Carolyn P Evan; Marina Kaymakcalan; Grace K Shaw; Philip W Kantoff; Mary-Ellen Taplin; Nimira S Alimohamed; Anthony M Joshua; Daniel Y C Heng; Christopher J Sweeney
Journal:  Clin Genitourin Cancer       Date:  2017-12-27       Impact factor: 2.872

Review 6.  Rationale for stereotactic body radiation therapy in treating patients with oligometastatic hormone-naïve prostate cancer.

Authors:  Onita Bhattasali; Leonard N Chen; Michael Tong; Siyuan Lei; Brian T Collins; Pranay Krishnan; Christopher Kalhorn; John H Lynch; Simeng Suy; Anatoly Dritschilo; Nancy A Dawson; Sean P Collins
Journal:  Front Oncol       Date:  2013-12-03       Impact factor: 6.244

7.  Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome.

Authors:  Giulia Riva; Giulia Marvaso; Matteo Augugliaro; Dario Zerini; Cristiana Fodor; Gennaro Musi; Ottavio De Cobelli; Roberto Orecchia; Barbara Alicja Jereczek-Fossa
Journal:  Ecancermedicalscience       Date:  2017-11-30

Review 8.  A comprehensive review of contemporary role of local treatment of the primary tumor and/or the metastases in metastatic prostate cancer.

Authors:  Fouad Aoun; Alexandre Peltier; Roland van Velthoven
Journal:  Biomed Res Int       Date:  2014-11-17       Impact factor: 3.411

Review 9.  The potential of multi-compound nanoparticles to bypass drug resistance in cancer.

Authors:  C G Da Silva; Godefridus J Peters; Ferry Ossendorp; Luis J Cruz
Journal:  Cancer Chemother Pharmacol       Date:  2017-09-08       Impact factor: 3.333

10.  Salvage Low Dose Rate Brachytherapy For Recurrent Prostate Cancer After External Beam Radiotherapy: Results From A Single Institution With Focus On Toxicity And Functional Outcomes.

Authors:  F Barbera; L Triggiani; M Buglione; P Ghirardelli; P Vitali; B Caraffini; P Borghetti; D Greco; L Bardoscia; N Pasinetti; L Costa; M Maddalo; B Ghedi; B La Face; S M Magrini
Journal:  Clin Med Insights Oncol       Date:  2017-11-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.